

CURRICULUM VITAE EUROPASS



INFORMAZIONI PERSONALI

Name	MARIA GRAZIA GHI
Address	ISTITUTO ONCOLOGICO VENETO IRCCS MEDICAL ONCOLOGY UNIT 2 VIA GATTAMELATA 64 35128, PADOVA - ITALY
Phone	+ 39-0498215931
Fax	+ 39-0498215932
E-mail	mariagrazia.ghi@iov.veneto.it
Nationality	Italian
Dob	11 TH MAY 1966

PROFESSIONAL POSITIONS

- Date May 2017 - present
Full time Medical Oncologist at the Medical Oncology Unit 2, Istituto Oncologico Veneto, IRCCS- Padova (Italy)
- Date January 2001 - April 2017
Full time Medical Oncologist at the Medical Oncology Department, Azienda ULSS 12 Veneziana, Venice and Mestre (Italy)
- Date October 2006-November 2006:
Visiting Scientist at the University of Chicago Medical Center- Illinois, Division of Hematology and Oncology (Dir. Prof E. Vokes)
- Date August 1999 - July 2000
Temporary assistant Medical Oncologist at the Medical Oncology Department, Azienda ULSS 12 Veneziana, Venice and Mestre (Italy)
- Date December 1998 - April 1999
Temporary Assistant at the Medical Oncology Department, Ospedale Regionale di Torrette, Ancona (Italy)

OTHER PROFESSIONAL EXPERIENCES

2009- present
Board member of the medical task force for the Italian guidelines regarding the treatment of Head and Neck Cancer for the Italian Association of Medical Oncology (access online from the website www.aiom.it) and for the Italian Association of Head and Neck Oncology (access online from the website www.aiocc.it)

December 2014 - present
Board member of the Regional Coordinators for the Head and Neck network (PDTA) in the Veneto region

November 2010 - March 2017
Member of the Ethics Committee of the Province of Venice

February 2010 – December 2012
Member of the Commissione Terapeutica Ospedaliera di Area Vasta Venezia-Rovigo in the Veneto region

January 2010 - December 2012
Coordinator of the Operative Center for Clinical Trials at the Medical Oncology Department, Azienda ULSS 12 Veneziana, Venice and Mestre

EDUCATION

1993
Degree in Medicine, 110/110 cum laude (University of Sassari, Italy)

1993
Italian certificate of licensure to practice medicine

1998
Postgraduate specialization in Medical Oncology, 50/50 cum laude (University of Ancona, Italy)

MOTHER TONGUE

Italian

OTHER LANGUAGES

English

RESEARCH FIELDS OF INTEREST

Head and Neck cancer

MEMBERSHIPS

American Society of Clinical Oncology (ASCO)
Italian Association of Medical Oncology (AIOM)
Italian Association of Head and Neck Oncology (AIOCC)

ORAL PRESENTATION AT INTERNATIONAL MEETINGS

- March 2018. **Advanced in Head and Neck cancer**. Induction chemotherapy: Which patients? When? How? **Lisbona (Portugal)**
- March 2016. **7 Reunion d' Oncologie ORL de la Mediterranee. ROOM VII. Saint-Paul de Vence, (France)**
- July 2016: **12th International SVO conference on head and neck cancer. Venezia Mestre (Italy)**
- November 2015: **Expert practice in Head and Neck cancer, Suzhou (Cina)**
- March 2015: **9° MACC meeting. Saint-Paul de Vence (France),**
- 12-14 February 2015: **ESTRO, ICHNO meeting 2015, Nizza (France),.**
- June 2014: **ASCO meeting 2014, Chicago (USA).**
- October 2014: **11th International SVO conference on head and neck cancer. Venezia Mestre (Italy),.**
- October 2013: **ASTRO meeting 2013, Atlanta (USA)**
- June 2013: **ASCO meeting 2013, Chicago (USA)**

SCIENTIFIC PUBLICATIONS

- September 2012: **ASTRO meeting 2012, Boston (USA).**
- Settembre 2012: **10th International SVO conference on head and neck cancer. Mogliano Veneto**

- **Ghi MG**, Paccagnella A. Therapeutic Intensification and Induction chemotherapy for High-Risk locally advanced Squamous cell carcinoma. Curr Treat Options Oncol. 2019 Jan 11;20(2):2. doi: 10.1007/s11864-019-0599-4. Review.

- **Ghi MG**, Ferrari D. Reply to the letter to the editor 'Concurrent cisplatin and radiotherapy versus cetuximab and radiotherapy, an unsolved problem' by Guler et al. Ann Oncol. 2018 Mar 1;29(3):779-780. doi: 10.1093/annonc/mdy016. No abstract available.

- **Ghi MG**, Paccagnella A, Ferrari D et al: Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer. A phase II-III trial. Ann Oncol. 2017 Sep 1;28(9):2206-2212. doi: 10.1093/annonc/mdx299.

- Machiels JP, Haddad RI, Fayette J et al: Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial.

Collaborators: Marc Alfonsi, Miguel Angel Alvarez Avitia, Rita Axelrod, Thomas Bauernhofer, Marco Benasso, Salam Billan, Tim Henrik Brümmendorf, Barbara Burtness, Francesco Caponigro, Gilberto Castro Jr, Paul Clement, Joseph M.del Campo, Didier Cupissol, Marian Degardin, Andreas Dietz, Lydia Mary Dreosti, Caroline Even, Jérôme Fayette, Francesco Ferrau, Gunnar Folprecht, Georgios Fountzilas, Jose Mario Freue, Hirofumi Fujii, Masato Fujii, Rinat Galiulin, Thomas Gauler, Vittorio Gebbia, Lionel Geoffrois, Vassilis Georgoulas, Raul Eduardo Giglio, **Maria Grazia Ghi**, Iris Gluck, Juan Jose Grau, Richard Greil, Viktor Grünwald, Joël Guigay, Orlando Guntinas-Lichius, Robert I. Haddad, Daniel Herchenhorn, Petra Holeckova, Hana Honova, Karl Hörmann, Adel Izmailov, Stefan Kasper, Takakuni Kato, Ulrich Keilholz, Roger Keresztes, Naomi Kiyota, Igor Kiselev, James Knost, Hiromi Kojima, Gabriela Kornek, Mark Kozloff, Nicolas Silva Lazaretti, Christophe Le Tourneau, Lisa F. Licitra, Clelia Madeddu, Jean-Pascal H. Machiels, Giovanni Mantovani, Koji Matsumoto, Kazuto Matsuura, Ranee Mehra, Bohuslav Melichar, Marco Merlano, Nobuya Monden, Kei Muro, Ulisses Ribaldo Nicolau, Gianmauro Numico, Jan Nyman, Kenji Okami, Sergey Orlov, Rodrigo Perez Pereira, Frédéric Peyrade, Angelika Pichler, Aron Popovtzer, Diamanto Psyrri, Daniel Rauch, Oscar Reig, Frédéric Rolland, Ilya Romanov, Sylvie Rottey, Jordi Rubió, Paul Ruff, Enzo Maria Ruggeri, Philippe Schafhausen, Jose Getulio Martins Segalla, Luciano de Souza Viana, Pol Specenier, Lena Specht, Jan Stöhlmacher, Yungpo Bernard Su, Makoto Tahara, Shunji Takahashi, Isabelle Tennevet, Christoph Tinchon, Jean-Marc Tourani, Jose Manuel Trigo, Javier Martínez Trufero, Vladimir Vladimirov, Toshinari Yagi, Tomoya Yokota, Kunitoshi Yoshino, Sylvie Zanetta-Devauges

- Mirabile A, Numico G, Russi EG, Bossi P, Crippa F, Bacigalupo A, De Sanctis V, Musso S, Merlotti A, **Ghi MG**, Merlano MC, Licitra L, Moretto F, Denaro N, Caspiani O, Buglione M, Pergolizzi S, Cascio A, Bernier J, Raber-Durlacher J, Vermorken JB, Murphy B, Ranieri MV, Dellinger RP: [Sepsis in head and neck](#)

[cancer patients treated with chemotherapy and radiation: Literature review and consensus](#). Crit Rev Oncol Hematol. 2015 Mar 19. pii: S1040-8428(15)00050-5. doi: 10.1016/j.critrevonc.2015.03.003. [Epub ahead of print] Review.

- Nwizu T, **Ghi MG**, Cohen EE, Paccagnella A: [The role of chemotherapy in locally advanced head and neck squamous cell carcinoma](#). Semin Radiat Oncol. 2012 Jul;22(3):198-206.
- Paccagnella, C. Mastromauro, P. D'Amanzo, **MG. Ghi**: Induction chemotherapy before chemoradiotherapy in locally advanced head and neck cancer: the future? [Oncologist](#) 2010; 15 Suppl 3: 8-12
- A Paccagnella, **MG Ghi**, L Loreggian et al: Concomitant chemoradiotherapy versus induction docetaxel, cisplatin and 5 fluorouracil (TPF) followed by concomitant chemoradiotherapy in locally advanced head and neck cancer: a phase II randomized study. [Annals of Oncology](#) 2009, Advance Access published December 23, 2009
- Apolone G, Corli O, Negri E et al: cancer pain outcome Research study group (CPOR SG) Investigators. Pattern and quality of care of cancer pain management. Results from the cancer pain Outcome Research Study Group. [Br J Cancer](#) 2009; 100 (10) 1566-1574

Collaborators: [Apolone G](#), [Bertetto O](#), [Caraceni A](#), [Corli O](#), [De Conno F](#), [Labianca R](#), [Maltoni M](#), [Nicora MF](#), [Torri V](#), [Zucco F](#), [Adamo V](#), [Airolidi M](#), [Allegri M](#), [Altavilla G](#), [Azzarello G](#), [Bandieri E](#), [Barzelloni ML](#), [Bassan F](#), [Belfiore G](#), [Bernardo G](#), [Bersano G](#), [Bertè R](#), [Bertetto O](#), [Bianchessi C](#), [Bologna A](#), [Bravi S](#), [Buono A](#), [Buzzi F](#), [Cacioppo C](#), [Capuccini J](#), [Caroti C](#), [Castagnini G](#), [Ceste M](#), [Chisari S](#), [Chiurazzi B](#), [Comandone A](#), [Cortesi E](#), [Crispino C](#), [Cuomo A](#), [De Martino A](#), [De Matteis A](#), [De Salve A](#), [Del Prete S](#), [Della Rovere F](#), [Dello Ioio C](#), [Derni S](#), [Di Alesio L](#), [Di Costanzo F](#), [Di Fonzo C](#), [Di Gregorio R](#), [Di Lanno M](#), [Di Seri M](#), [Di Stefano M](#), [Dini D](#), [Dini D](#), [Duro M](#), [Facchini G](#), [Farris A](#), [Ferrara C](#), [Ferrari P](#), [Frascaroli M](#), [Furiosi D](#), [Fusco F](#), [Gebbia V](#), **[Ghi MG](#)**, [Giannunzio D](#), [Giuffrè C](#), [Guarino C](#), [Henriquet F](#), [Isa L](#), [La Ciura P](#), [La Rocca F](#), [Labianca R](#), [Longhi C](#), [Lupo G](#), [Mameli S](#), [Manni A](#), [Manzione L](#), [Martini C](#), [Martoni A](#), [Marzano N](#), [Masseroni S](#), [Mattioli V](#), [Maurizi P](#), [Miotti D](#), [Montanari L](#), [Moschetti L](#), [Murgia V](#), [Nardi LF](#), [Narducci F](#), [Negri F](#), [Orlandini C](#), [Ottaviani D](#), [Pancera G](#), [Paoletti F](#), [Pappalardo A](#), [Paris MK](#), [Pittureri C](#), [Piva L](#), [Ponchio L](#), [Reale C](#), [Rinaldi A](#), [Romagnoli E](#), [Russo A](#), [Sandomenico C](#), [Sbanotto A](#), [Scanzi F](#), [Schiavetto I](#), [Trentin L](#), [Tucci M](#), [Vaccaro G](#), [Valenti D](#), [Valori VM](#), [Vasini G](#), [Veltri E](#), [Zagonel V](#), [Zecca E](#), [Zeppetella G](#), [Ziliotti M](#), [Zucco F](#)

- A.Paccagnella,F. Oniga,A. Bearz, A. Favaretto, M Clerici, F. Barbieri, A. Riccardi, A. Chella. G. CeresoliS. Tumolo, R. Ridolfi, U. Tirelli R. Biason, F. Veglia, **MG Ghi**. **Adding Gemcitabine to Paclitaxel/Carboplatin combination increase survival in advanced Non Small Cell Lung Cancer: Results of a phase II-III study**. [Journal of Clinical Oncology](#) 2006; 24:681.
- Zorat PL, Paccagnella A, Cavaniglia G, Loreggian L, Gava A, Mione CA, Boldrin F, Marchiori C, Lunghi F, fede A, Bordin A, Da Mosto MC, Sileni VC, Orlando A, Jirillo A, Tomio L, Pappagallo GL, **Ghi MG**: Randomized phase III trial of neoadjuvant chemotherapy in head and neck cancer: 10-year

follow-up. Journal of the National Cancer Institute 2004 Nov 17; 96 (22): 1714- 1717.

- **MG Ghi**, A. Paccagnella, P. D'Amanzo, Mione CA, Fasan S, Paro S, Mastromauro C, Carnuccio R, Turcato G, Gatti C, Pallini A, Nascimben O, Biason R, Oniga F, Medici M Rossi F, Fila G: Neoadjuvant Docetaxel /Cisplatin /Fluorouracil (TPF) before concurrent chemo-radiotherapy (CT-RT) in locally advanced Squamous Cell Carcinoma (SCC) of Head and Neck versus concomitant CT-RT alone. A phase II feasibility study. Int. J. Radiation Oncology Biol. Phys. 2004, Vol. 59, No. 2, pp. 481–487.
- Favaretto, S Aversa, A Paccagnella, V De Pangher, V PalmisanoA. Paccagnella, A. Favaretto, F. Oniga, F. Barbieri, G. Ceresoli W. Torri, Villa E, Verusio C, Cetto GL, Santo A, De Pangher V, Artioli F, Cacciani GC, Parodi G, Soresi F, **Ghi MG**, Morabito A, Biason R, Giusto M, Mosconi P, Chiarion-SieniV: Cisplatin versus carboplatin in combination with mytomicin and vinblastine in advanced NSCLC- A Multicenter randomized phase III trial. Lung Cancer 2004, 43 (1): 83-91.
- A Paccagnella, F Oniga, A Favaretto, R Biason and **MG Ghi**. Elderly patients with small cell lung cancer. Tumori 2002; 88 (Suppl. 1):S145-147.
- Cascinu S, Battelli N, Graziano F, **Ghi MG**, Silva RR, Nacciarriti D, Cellerino R: C-erbB-2 and common prognostic factors in breast cancer patients. Oncology Reports 3: 883-886, 1996;

11 May 2019

Dr Maria Grazia Ghi



27 November 2018

Maria Grazia Ghi